FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Henning Schulze-Bergkamen

Research Profile

Chemicals & Drugs

Disorders

Anatomy

Physiology

Co-author Network

Publications

TOP 3
Marcus A Wörns; Peter R Galle; Thomas Gamstätter; Sandra Koch; Jens U Marquardt; Marc Nguyen-Tat; Ina M Niederle; Marcus Schuchmann; Henning Schulze-Bergkamen; Arndt Weinmann
The impact of patient and tumour baseline characteristics on the overall survival of patients with advanced hepatocellular carcinoma treated with sorafenib.
Toni Urbanik; Ari Waisman; Marcus A Wörns; Katharina Becker; Regina Johanna Boger; Karl Roland Ehrenberg; Matthias Hahn; Nadine Hövelmeyer; Dirk Jäger; Thomas Longerich; Marcus Schuchmann; Henning Schulze-Bergkamen
Liver specific deletion of CYLDexon7/8 induces severe biliary damage, fibrosis and increases hepatocarcinogenesis in mice.
Helge Bruns; Ingo Watanpour; Martha Maria Gebhard; Christa Flechtenmacher; Uwe Matthias Galli; Henning Schulze-Bergkamen; Markus Zorn; Markus W Büchler; Peter Schemmer
Glycine and taurine equally prevent fatty livers from Kupffer cell-dependent injury: an in vivo microscopy study.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Henning Schulze-Bergkamen (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Marcus A Wörns; Peter R Galle; Thomas Gamstätter; Sandra Koch; Jens U Marquardt; Marc Nguyen-Tat; Ina M Niederle; Marcus Schuchmann; Henning Schulze-Bergkamen; Arndt Weinmann
The impact of patient and tumour baseline characteristics on the overall survival of patients with advanced hepatocellular carcinoma treated with sorafenib.
Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 2013;45(5):408-13.
2012: Toni Urbanik; Ari Waisman; Marcus A Wörns; Katharina Becker; Regina Johanna Boger; Karl Roland Ehrenberg; Matthias Hahn; Nadine Hövelmeyer; Dirk Jäger; Thomas Longerich; Marcus Schuchmann; Henning Schulze-Bergkamen
Liver specific deletion of CYLDexon7/8 induces severe biliary damage, fibrosis and increases hepatocarcinogenesis in mice.
Journal of hepatology 2012;57(5):995-1003.
2011: Helge Bruns; Ingo Watanpour; Martha Maria Gebhard; Christa Flechtenmacher; Uwe Matthias Galli; Henning Schulze-Bergkamen; Markus Zorn; Markus W Büchler; Peter Schemmer
Glycine and taurine equally prevent fatty livers from Kupffer cell-dependent injury: an in vivo microscopy study.
Microcirculation (New York, N.Y. : 1994) 2011;18(3):205-13.
2011: Toni Urbanik; Bruno Christian Köhler; Regina Johanna Boger; Marcus A Wörns; Steffen Heeger; Gerd Otto; Nadine Hövelmeyer; Peter Robert Galle; Marcus Schuchmann; Ari Waisman; Henning Schulze-Bergkamen
Down-regulation of CYLD as a trigger for NF-κB activation and a mechanism of apoptotic resistance in hepatocellular carcinoma cells.
International journal of oncology 2011;38(1):121-31.
2010: Achim Weber; Regina Boger; Binje Vick; Toni Urbanik; Johannes Haybaeck; Stefan Zoller; Andreas Teufel; Peter H Krammer; Joseph T Opferman; Peter R Galle; Marcus Schuchmann; Mathias Heikenwalder; Henning Schulze-Bergkamen
Hepatocyte-specific deletion of the antiapoptotic protein myeloid cell leukemia-1 triggers proliferation and hepatocarcinogenesis in mice.
Hepatology (Baltimore, Md.) 2010;51(4):1226-36.
2009: Bruno-Christian Koehler; Toni Urbanik; Binje Vick; Regina-Johanna Boger; Steffen Heeger; Peter-R Galle; Marcus Schuchmann; Henning Schulze-Bergkamen
TRAIL-induced apoptosis of hepatocellular carcinoma cells is augmented by targeted therapies.
World journal of gastroenterology : WJG 2009;15(47):5924-35.
2009: Henning Schulze-Bergkamen; Arndt Weinmann; Markus Moehler; Juergen Siebler; Peter Galle
Novel ways to sensitise gastrointestinal cancer to apoptosis.
Gut 2009;58(7):1010-24.
2009: Marcus Alexander Wörns; Arndt Weinmann; Kerstin Pfingst; Carla Schulte-Sasse; Claudia M Messow; Henning Schulze-Bergkamen; Andreas Teufel; Marcus Schuchmann; Stephan Kanzler; Christoph Düber; Gerd Otto; Peter Robert Galle
Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis.
Journal of clinical gastroenterology 2009;43(5):489-95.
2009: Kerstin Herzer; Thomas G Hofmann; Andreas Teufel; Carl C Schimanski; Markus Moehler; Stephan Kanzler; Henning Schulze-Bergkamen; Peter R Galle
IFN-alpha-induced apoptosis in hepatocellular carcinoma involves promyelocytic leukemia protein and TRAIL independently of p53.
Cancer research 2009;69(3):855-62.
2009: Binje Vick; Achim Weber; Toni Urbanik; Thorsten Maass; Andreas Teufel; Peter H Krammer; Joseph T Opferman; Marcus Schuchmann; Peter R Galle; Henning Schulze-Bergkamen
Knockout of myeloid cell leukemia-1 induces liver damage and increases apoptosis susceptibility of murine hepatocytes.
Hepatology (Baltimore, Md.) 2009;49(2):627-36.
2008: Henning Schulze-Bergkamen; Roland Ehrenberg; Lothar Hickmann; Binje Vick; Toni Urbanik; Carl C Schimanski; Martin-R Berger; Arno Schad; Achim Weber; Steffen Heeger; Peter Galle; Markus Moehler
Bcl-x(L) and Myeloid cell leukaemia-1 contribute to apoptosis resistance of colorectal cancer cells.
World journal of gastroenterology : WJG 2008;14(24):3829-40.
2007: Andreas Teufel; Frank Staib; Stephan Kanzler; Arndt Weinmann; Henning Schulze-Bergkamen; Peter Galle
Genetics of hepatocellular carcinoma.
World journal of gastroenterology : WJG 2007;13(16):2271-82.
2006: Stefanie C Fas; Sven Baumann; Andreas Krueger; Christian R Frey; Henning Schulze-Bergkamen; Dirk Brenner; Christine Stumpf; Kathrin Kappes; Peter H Krammer
In vitro generated human memory-like T cells are CD95 type II cells and resistant towards CD95-mediated apoptosis.
European journal of immunology 2006;36(11):2894-903.
2006: Michael A Kern; Anke Maria Haugg; Andreas F Koch; Tobias Schilling; Kai Breuhahn; Henning Walczak; Binje Fleischer; Christian Trautwein; Christoph W Michalski; Henning Schulze-Bergkamen; Helmut Friess; Wolfgang Stremmel; Peter H Krammer; Peter Schirmacher; Martina Müller
Cyclooxygenase-2 inhibition induces apoptosis signaling via death receptors and mitochondria in hepatocellular carcinoma.
Cancer research 2006;66(14):7059-66.
2006: Henning Schulze-Bergkamen; Marcus Schuchmann; Binje Fleischer; Peter R Galle
The role of apoptosis versus oncotic necrosis in liver injury: facts or faith?
Journal of hepatology 2006;44(5):984-93.
2006: Tom M Ganten; Ronald Koschny; Jaromir Sykora; Henning Schulze-Bergkamen; Peter Büchler; Tobias L Haas; Manuela B Schader; Andreas Untergasser; Wolfgang Stremmel; Henning Walczak
Preclinical differentiation between apparently safe and potentially hepatotoxic applications of TRAIL either alone or in combination with chemotherapeutic drugs.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(8):2640-6.
2006: Henning Schulze-Bergkamen; Binje Fleischer; Marcus Schuchmann; Achim Weber; Arndt Weinmann; Peter H Krammer; Peter R Galle
Suppression of Mcl-1 via RNA interference sensitizes human hepatocellular carcinoma cells towards apoptosis induction.
BMC cancer 2006;6():232.
2006: Marcus Schuchmann; Henning Schulze-Bergkamen; Binje Fleischer; Jörn M Schattenberg; Juergen Siebler; Arndt Weinmann; Andreas Teufel; Marcus A Wörns; Thomas Fischer; Susanne Strand; Ansgar W Lohse; Peter R Galle
Histone deacetylase inhibition by valproic acid down-regulates c-FLIP/CASH and sensitizes hepatoma cells towards CD95- and TRAIL receptor-mediated apoptosis and chemotherapy.
Oncology reports 2006;15(1):227-30.
2006: Binje Fleischer; Henning Schulze-Bergkamen; Marcus Schuchmann; Achim Weber; Stefan Biesterfeld; Martina Müller; Peter H Krammer; Peter R Galle
Mcl-1 is an anti-apoptotic factor for human hepatocellular carcinoma.
International journal of oncology 2006;28(1):25-32.
2005: M Müller; Tobias Schilling; emre sayan; A Kairat; K Lorenz; Henning Schulze-Bergkamen; M Oren; A Koch; Andrea Tannapfel; Wolfgang Stremmel; Gerry Melino; Peter H Krammer
TAp73/Delta Np73 influences apoptotic response, chemosensitivity and prognosis in hepatocellular carcinoma.
Cell death and differentiation 2005;12(12):1564-77.
2005: Andrea Schulze-Bergkamen; Jürgen G Okun; Ute Spiekerkötter; Martin Lindner; Dorothea Haas; Dirk Kohlmüller; Ertan Mayatepek; Henning Schulze-Bergkamen; Cheryl R Greenberg; Johannes Zschocke; Georg F Hoffmann; Stefan Kölker
Quantitative acylcarnitine profiling in peripheral blood mononuclear cells using in vitro loading with palmitic and 2-oxoadipic acids: biochemical confirmation of fatty acid oxidation and organic acid disorders.
Pediatric research 2005;58(5):873-80.
2005: Olav Gressner; Tobias Schilling; Katja Lorenz; Elisa Schulze Schleithoff; Andreas Koch; Henning Schulze-Bergkamen; Anna Maria Lena; Eleonora Candi; Alessandro Terrinoni; Maria Valeria Catani; Moshe Oren; Gerry Melino; Peter H Krammer; Wolfgang Stremmel; Martina Müller
TAp63alpha induces apoptosis by activating signaling via death receptors and mitochondria.
The EMBO journal 2005;24(13):2458-71.
2005: Kerstin Herzer; Tom M Ganten; Henning Schulze-Bergkamen; Anne Grosse-Wilde; Ronald Koschny; Peter H Krammer; Henning Walczak
Transforming growth factor beta can mediate apoptosis via the expression of TRAIL in human hepatoma cells.
Hepatology (Baltimore, Md.) 2005;42(1):183-92.
2004: Jürgen Pohl; Axel Ring; Robert Ehehalt; Henning Schulze-Bergkamen; Arno Schad; Paul Verkade; Wolfgang Stremmel
Long-chain fatty acid uptake into adipocytes depends on lipid raft function.
Biochemistry 2004;43(14):4179-87.
2004: Henning Schulze-Bergkamen; Dirk Brenner; Andreas Krueger; Dorothee Suess; Stefanie C Fas; Christian R Frey; Andreas Dax; Dorothea Zink; Peter Büchler; Martina Müller; Peter H Krammer
Hepatocyte growth factor induces Mcl-1 in primary human hepatocytes and inhibits CD95-mediated apoptosis via Akt.
Hepatology (Baltimore, Md.) 2004;39(3):645-54.
2004: Henning Schulze-Bergkamen; Peter H Krammer
Apoptosis in cancer--implications for therapy.
Seminars in oncology 2004;31(1):90-119.
2003: Ingo Schmitz; Andreas Krueger; Sven Baumann; Henning Schulze-Bergkamen; Peter H Krammer; Sabine Kirchhoff
An IL-2-dependent switch between CD95 signaling pathways sensitizes primary human T cells toward CD95-mediated activation-induced cell death.
Journal of immunology (Baltimore, Md. : 1950) 2003;171(6):2930-6.
2003: Henning Schulze-Bergkamen; Andreas Untergasser; Andreas Dax; Heiko Vogel; Peter Büchler; Ernst Klar; Thomas Lehnert; Helmut Friess; Markus W Büchler; Michael Kirschfink; Wolfgang Stremmel; Peter H Krammer; Martina Müller; Ulrike Protzer
Primary human hepatocytes--a valuable tool for investigation of apoptosis and hepatitis B virus infection.
Journal of hepatology 2003;38(6):736-44.
2002: Henning Schulze-Bergkamen; Ivan Zuna; Andreas Teufel; Wolfgang Stremmel; Jochen Rudi
Treatment of advanced gastric cancer with etoposide, folinic acid, and fluorouracil in the clinical setting: efficacy of therapy and value of serum tumor markers.
Medical oncology (Northwood, London, England) 2002;19(1):43-53.
1997: Michael Heike; Rainer Duchmann; Ekkehard May; Henning Schulze-Bergkamen; Ute Schmitt; Karl-Hermann Meyer zum Büschenfelde
Dominant TCRB-V-J chain usage and clonal expansion of sarcoma-reactive CD4+ HLA-DR-restricted T cells suggest a limited set of immunodominant sarcoma antigens.
International journal of cancer. Journal international du cancer 1997;72(3):403-7.
1997: Michael Heike; Joerg F Schlaak; S Heyl; Henning Schulze-Bergkamen; Ute Schmitt; Karl-Hermann Meyer zum Büschenfelde
Contrary roles of IL-4 and IL-12 on IL-10 production and proliferation of human tumour reactive T cells.
Scandinavian journal of immunology 1997;45(2):221-6.
1996: Michael Heike; Joerg F Schlaak; Henning Schulze-Bergkamen; S Heyl; W Herr; U Schmitt; Peter M Schneider; K H Meyer zum Büschenfelde
Specificities and functions of CD4+ HLA class II-restricted T cell clones against a human sarcoma: evidence for several recognized antigens.
Journal of immunology (Baltimore, Md. : 1950) 1996;156(6):2205-13.